Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives

Forensic Science International

Volumn 198, Issue 1-3, 2010, Pages 58-61

  Cone, Edward J ^a   Zichterman, Anne ^b   Heltsley, Rebecca ^b   Black, David L ^b   Cawthon, Beverly ^b   Robert, Tim ^b   Moser, Frank ^b   Caplan, Yale H ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Aegis Sciences Corporation   (United States)

^c National Scientific Services   (United States)

Author keywords

Compliance monitoring; Normetabolites; Opiates; Urine

Indexed keywords

BETA GLUCURONIDASE; CODEINE; DIHYDROCODEINE; DRUG METABOLITE; HYDROCODONE; ILLICIT DRUG; MORPHINE; NORCODEINE; NORHYDROCODONE; NOROXYCODONE; OPIATE; OXYCODONE; OXYMORPHONE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG ABUSE; DRUG TRANSFORMATION; FALSE NEGATIVE RESULT; HUMAN; HYDROLYSIS; LIQUID CHROMATOGRAPHY; PATIENT ATTITUDE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 77952288931     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2009.12.005     Document Type: Article

References (17)

1. Kuehn B.M. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007, 297:249-251.
2. Katz N., Fanciullo G.J. Role of urine toxicology testing in the management of chronic opioid therapy. Clin. J. Pain 2002, 18:S76-S82.
3. Kuehn B.M. Prescription drug abuse rises globally. JAMA 2007, 297:1306.
4. Gourlay D.L., Heit H.A., Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005, 6:107-112.
5. Heit H.A., Gourlay D.L. Urine drug testing in pain medicine. J. Pain Symptom Manage. 2004, 27:260-267.
6. Cone E.J., Caplan Y.H. Urine toxicology testing in chronic pain management. Postgrad. Med. 2009, 121:91-102.
7. Cone E.J., Welch P., Paul B.D., Mitchell J.M. Forensic drug testing for opiates. III. Urinary excretion rates of morphine and codeine following codeine administration. J. Anal. Toxicol. 1991, 15:161-166.
8. Smith M.L., Hughes R.O., Levine B., Dickerson S., Darwin W.D., Cone E.J. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J. Anal. Toxicol. 1995, 19:18-26.
9. Caraco Y., Sheller J., Wood A.J. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. J. Pharmacol. Exp. Ther. 1997, 281:330-336.
10. Otton S.V., Schadel M., Cheung S.W., Kaplan H.L., Sellers E.M. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 1993, 54:463-472.
11. Otton S.V., Wu D., Joffe R.T., Cheung S.W., Sellers E.M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. 1993, 53:401-409.
12. Cone E.J., Caplan Y.H., Black D.L., Robert T., Moser F. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J. Anal. Toxicol. 2008, 32:530-543.
13. Oyler J.M., Cone E.J., Joseph R.E., Huestis M.A. Identification of hydrocodone in human urine following controlled codeine administration. J. Anal. Toxicol. 2000, 24:530-535.
14. Hutchinson M.R., Menelaou A., Foster D.J., Coller J.K., Somogyi A.A. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br. J. Clin. Pharmacol. 2004, 57:287-297.
15. Cone E.J., Darwin W.D., Gorodetzky C.W., Tan T. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab. Dispos. 1978, 6:488-493.
16. Lalovic B., Phillips B., Risler L.L., Howald W., Shen D.D. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos. 2004, 32:447-454.
17. Lalovic B., Kharasch E., Hoffer C., Risler L., Liu-Chen L.Y., Shen D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. 2006, 79:461-479.